Home > Healthcare > Pharmaceuticals > Finished Drug Form > hydroxyzine market
Get a free sample of Hydroxyzine Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Get a free sample of Hydroxyzine Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
The hydroxyzine sector is competitive in nature, with a mix of major global and smaller to medium-sized companies competing for market share. A pivotal aspect of market strategy involves the continual introduction of innovative products leveraging diverse technologies. Notably, prominent industry players command significant influence in this dynamic landscape, often driving forward advancements through substantial investments in research and development. Additionally, strategic alliances, acquisitions, and mergers are instrumental in fortifying market positions and expanding global footprint amidst evolving regulatory landscapes.
Some of the eminent market participants operating in the hydroxyzine industry include:
Alliance Pharma Plc, Amneal Pharmaceuticals, Inc., Aurobindo Pharma Limited, Glenmark Pharmaceuticals Ltd., MYLAN N.V., Novartis AG, Pfizer Inc., Piramal Enterprises Limited, Sun Pharmaceutical Industries Limited and Teva Pharmaceutical Industries Limited.
The U.S. market size was USD 290 million in 2023, owing to continuous innovation by pharmaceutical companies in the country.
The tablets segment in the hydroxyzine market is likely to reach USD 557.1 million by 2032, propelled by the advancements in pharmaceutical formulation technologies that enhance the bioavailability and efficacy of hydroxyzine tablets.
Market size for hydroxyzine was valued at USD 784.4 million in 2023 and is estimated to grow at 5.4% CAGR from 2024 to 2032, driven by increasing allergic reaction among the target population.